These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577 [TBL] [Abstract][Full Text] [Related]
6. Toxic Feedback Loop Involving Iron, Reactive Oxygen Species, α-Synuclein and Neuromelanin in Parkinson's Disease and Intervention with Turmeric. Jansen van Rensburg Z; Abrahams S; Bardien S; Kenyon C Mol Neurobiol; 2021 Nov; 58(11):5920-5936. PubMed ID: 34426907 [TBL] [Abstract][Full Text] [Related]
7. In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease. Gonzalez-Sepulveda M; Compte J; Cuadros T; Nicolau A; Guillard-Sirieix C; Peñuelas N; Lorente-Picon M; Parent A; Romero-Giménez J; Cladera-Sastre JM; Laguna A; Vila M Brain; 2023 Mar; 146(3):1040-1052. PubMed ID: 36717986 [TBL] [Abstract][Full Text] [Related]
8. Neuromelanin in Parkinson's Disease: Tyrosine Hydroxylase and Tyrosinase. Nagatsu T; Nakashima A; Watanabe H; Ito S; Wakamatsu K Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456994 [TBL] [Abstract][Full Text] [Related]
9. Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates. Chocarro J; Rico AJ; Ariznabarreta G; Roda E; Honrubia A; Collantes M; Peñuelas I; Vázquez A; Rodríguez-Pérez AI; Labandeira-García JL; Vila M; Lanciego JL Brain; 2023 Dec; 146(12):5000-5014. PubMed ID: 37769648 [TBL] [Abstract][Full Text] [Related]
10. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation. Liu G; Yu J; Ding J; Xie C; Sun L; Rudenko I; Zheng W; Sastry N; Luo J; Rudow G; Troncoso JC; Cai H J Clin Invest; 2014 Jul; 124(7):3032-46. PubMed ID: 24865427 [TBL] [Abstract][Full Text] [Related]
11. Increased expression of α-synuclein in aged human brain associated with neuromelanin accumulation. Xuan Q; Xu SL; Lu DH; Yu S; Zhou M; Uéda K; Cui YQ; Zhang BY; Chan P J Neural Transm (Vienna); 2011 Nov; 118(11):1575-83. PubMed ID: 21461961 [TBL] [Abstract][Full Text] [Related]
12. Preclinical signs of Parkinson's disease: A possible association of Parkinson's disease with skin and hair features. Jucevičiūtė N; Banaitytė I; Vaitkus A; Balnytė R Med Hypotheses; 2019 Jun; 127():100-104. PubMed ID: 31088630 [TBL] [Abstract][Full Text] [Related]
13. Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease. Vila M Mov Disord; 2019 Oct; 34(10):1440-1451. PubMed ID: 31251435 [TBL] [Abstract][Full Text] [Related]
14. Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease. Chu Y; Morfini GA; Kordower JH J Parkinsons Dis; 2016; 6(1):77-97. PubMed ID: 27003787 [TBL] [Abstract][Full Text] [Related]
15. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Recasens A; Dehay B; Bové J; Carballo-Carbajal I; Dovero S; Pérez-Villalba A; Fernagut PO; Blesa J; Parent A; Perier C; Fariñas I; Obeso JA; Bezard E; Vila M Ann Neurol; 2014 Mar; 75(3):351-62. PubMed ID: 24243558 [TBL] [Abstract][Full Text] [Related]
16. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678 [TBL] [Abstract][Full Text] [Related]
17. Neuromelanin and Parkinson's disease. Marsden CD J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645 [TBL] [Abstract][Full Text] [Related]
18. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254 [TBL] [Abstract][Full Text] [Related]
19. Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson's disease. Ikeda-Matsuo Y; Miyata H; Mizoguchi T; Ohama E; Naito Y; Uematsu S; Akira S; Sasaki Y; Tanabe M Neurobiol Dis; 2019 Apr; 124():81-92. PubMed ID: 30423474 [TBL] [Abstract][Full Text] [Related]
20. Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to alpha-synuclein. Fasano M; Giraudo S; Coha S; Bergamasco B; Lopiano L Neurochem Int; 2003 Jun; 42(7):603-6. PubMed ID: 12590943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]